Roivant Sciences (ROIV)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$34.93+1.51%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · ROIV
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -14.8% |
| Our one-year growth estimate | diamond | -60.0% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 45.2 percentage points more one-year growth.
The one-year revenue growth assumption on Valuation.
Model as of 2026-09-04 · Compared with 398 industry peers · Company calendar date is not available
ROIV — earnings in line
Dated 2026-08-06
Results of Operations and Financial Condition” (including Exhibit 99.1) shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be incorporated by reference in any filing made by the Company pursuant to the Securities Act of 1933, as amended, other than to the extent that such filing incorporates by reference any or all of such information by express reference thereto.
Why it matters: Higher operating income shows Roivant can control costs and grow.
Supportive ifOperating income is above $415.2M in the next earnings release.
Worry ifOperating income is below $415.2M in the next earnings release.
Why it matters: If sector growth slows, it could hurt Roivant's performance and outlook.
Worry ifSector revenue growth reported below its median in the next quarter.
Less concerning ifSector revenue growth remains above its median in the next quarter.
Why it matters: Data from this trial could grow Roivant's portfolio in pulmonary hypertension. Good results could help growth.
Supportive ifTopline data from the Phase 2 trial of mosliciguat in PH-ILD are reported in the second half of 2026.
Worry ifTopline data may be disappointing or delayed.
Why it matters: Topline data will show how well brepocitinib works in another use. This will affect future growth.
Watch forTopline data from the Phase 3 study in non-infectious uveitis shows good results.
Also watch forTopline data from the Phase 3 study in non-infectious uveitis shows bad results.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$149 on $10,000 · ±1.5% | How much price usually moves either way. |
| Bad day | $299 loss on $10,000 · 3.0% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $1,284 loss on $10,000 · 12.8% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: Achieving positive net income is a key goal for Roivant. It shows financial health.
Supportive ifNet income reported as positive in the next earnings release.
Worry ifNet income remains negative in the next earnings release.
Why it matters: Data from this trial will show how well IMVT-1402 works. This will affect investor confidence and future funding.
Watch forTopline data from the IMVT-1402 trial in cutaneous lupus shows good results.
Also watch forTopline data from the IMVT-1402 trial in cutaneous lupus shows bad results.
Why it matters: Updates on this trial could show the drug's potential. Good results could make investors more confident.
Supportive ifFurther updates on the IMVT-1402 trial are provided in the second half of 2026.
Worry ifNo updates are given or results are disappointing.
Why it matters: Better cash flow from operations is key for Roivant's financial health.
Supportive ifCash from operations is less negative than -$163.8M in the next earnings release.
Worry ifCash from operations is more negative than -$163.8M in the next earnings release.
Why it matters: Topline data could prove the drug works and help with future approvals.
Supportive ifTopline data from the Phase 3 trial of brepocitinib in uveitis come out in late 2026.
Worry ifTopline data are not released or show poor results.
Why it matters: Updates on cash will show if Roivant can keep running until it makes money.
Supportive ifRoivant says it has enough cash to keep running until it makes money.
Worry ifCash position drops a lot, raising worries about staying in business.